Clinical trials: Polyps of Colon
- Condition Polyps of Colon
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Adenomatous Polyposis Coli
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
To test whether celecoxib can be used to prevent colon polyp formation in children with familial adenomatous polyposis (FAP).
- Trial name
- CHIP (NCT00585312)
- Testing
- Celecoxib
- Where
- 42 sites in United States, Belgium and 12 more
- Volunteers
- 106 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Colorectal Neoplasms
Impact of Experience on Results With the Third Eye Retroscope
The Third Eye Retroscope is a device that can be used with a colonoscope to improve the ability of a physician to see areas of the colon that may be hidden from the view of the colonoscope.
- Trial name
- NCT00969124
- Testing
- Third Eye Retroscope
- Where
- 9 sites in United States
- Volunteers
- 328 people, healthy volunteers welcome
- Sponsor
- Avantis Medical Systems
Colorectal Cancer, Adenomatous Polyp of Colon
CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
The purpose of this study is to evaluate the performance of the SEPT9 gene methylation assay in Colorectal cancer (CRC) high-risk population in Chinese hospitals using the opportunistic screening method.
- Conditions
- Colorectal Cancer, Adenomatous Polyp of Colon, Polyps, Other Disease/Injury
- Trial name
- RESEPT (NCT02540850)
- Where
- 4 sites in China
- Volunteers
- 1,031 people, healthy volunteers welcome
- Sponsor
- BioChain (Beijing) Science and Technology, Inc.
Adenoma, Colo-rectal Cancer
Clinical Value of G-EYE Colonoscopy in Daily Practice for Adenoma Detection and Time for Polyp Removal
Colonoscopy parameters will be compared before the introduction of the G-EYE endoscope and after the introduction of the G-EYE endoscope
- Trial name
- NCT04767971
- Testing
- Standard Colonoscopy, G-EYE Colonoscopy
- Where
- Germany
- Volunteers
- 2,795 people, healthy volunteers welcome
- Sponsor
- Dr. Horst Schmidt Klinik GmbH
Adenomatous Polyposis Coli
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study…
- Trial name
- NCT04948398
- Testing
- Guselkumab
- Sponsor
- Janssen Research & Development, LLC